WASHINGTON - A new study has shown that the antidepressant amitriptyline is just as effective as placebo in treating pain-predominant gastrointestinal disorders in children.
“Many pharmaceutical products are prescribed for off-label use in children due to the lack of clinical trials testing the efficacy of the drugs in children and adolescents. Therefore, the pediatric gastroenterologist frequently has to make treatment decisions without the evidence of how drugs work in children,” said Dr. Miguel Saps, of Children’s Memorial Hospital and lead author of the study.
“The high placebo effect we identified in this study suggests that further studies of the use of certain antidepressants in children with functional bowel disorders are needed. While several trials have demonstrated a beneficial effect of antidepressants, including amitriptyline, for the treatment of irritable bowel syndrome (IBS) in adults, more research is needed to determine how effective this drug is, if at all, in children,” Dr. Saps added.
According to background information in an article on the study, published in the journal Gastroenterology, amitriptyline is used to treat symptoms of depression, but it is some times prescribed to children for pain relief from pain-predominant functional gastrointestinal disorders (FGIDs).
Pain-predominant FGIDs are among the most common causes for medical consultation in children. Such disorders include three common conditions: IBS, functional dyspepsia and functional abdominal pain.
For their study, the researchers designed a large prospective, multi-centre, randomised placebo-controlled trial in which children, ages eight to 17, with IBS, functional abdominal pain or functional dyspepsia were randomised to four weeks of placebo or amitriptyline.
Of the 83 children who completed the study, 63 percent of those who took amitriptyline reported feeling better, while 5 percent reported feeling worse.
Among those given a placebo, 57.5 percent felt better, while 2.5 percent felt worse.
Pain relief was excellent (7 percent), good (38 percent) in children on placebo and excellent (15 percent), good (35 percent) in children on amitriptyline.
The researchers observed that both amitriptyline and placebo were associated with excellent therapeutic response, although patients with mild to moderate intensity of pain responded better to treatment.
According to them, there was no significant difference between amitriptyline and placebo after four weeks of treatment.
In children, the use of drugs to treat pain-predominant FGIDs is mostly empirical and based on adult data.
There have been only a few small, randomised clinical trials evaluating the efficacy of drugs for the treatment of pain-predominant FGIDs in children. (ANI)
Related News
Antidepressant use during pregnancy puts newborns at increased health riskOctober 6th, 2009 WASHINGTON - Use of antidepressants during pregnancy might put the newborn child at increased health risk, according to researchers. The study led by Dr Najaaraq Lund showed that exposure to certain class of antidepressants can increase the risk of preterm birth, and can affect the overall health of the newborn.
Depomed says its post-shingles pain drug succeeded it trial, and shares hit three-year highOctober 5th, 2009 Depomed says shingles pain drug meets study goalMENLO PARK, Calif. — Depomed Inc.
Drug combo better than individual medications for treating chronic painOctober 1st, 2009 WASHINGTON - A combination of two commonly prescribed drugs offers a much more effective treatment for people with debilitating neuropathic pain than if they take either of the medications individually, according to a study by Queen's University researchers. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain than when they took one or the other individually, reports Dr.
How to make flu shots easier for kidsSeptember 27th, 2009 WASHINGTON - Kids often cry or scream when they are about to get an injection. Now, experts from Mattel Children's Hospital UCLA have offered certain tips to minimize the pain associated with the needlestick.
How infant pain has repercussions in adulthoodSeptember 26th, 2009 WASHINGTON - Researchers at Georgia State University have thrown light on how pain in infancy alters the brain's ability to process pain in adulthood. The study has now indicated that infants who spent time in the neonatal intensive care unit (NICU) show altered pain sensitivity in adolescence.
Arena diet drug lorcaserin succeeds in trial, but comes up short of competing drug candidatesSeptember 18th, 2009 Arena obesity drug falls short against other medsNEW YORK — Arena Pharmaceuticals Inc. said on Friday that its obesity drug candidate lorcaserin succeeded in a clinical study, but the drug did not appear to be as effective as other treatments competitors have in development.
Persistent pain in younger people ages them by 20 yearsSeptember 17th, 2009 WASHINGTON - Persistent pain in younger people ages them by 20 to 30 years in terms of physical abilities, a new study suggests. The study established that people with pain develop functional limitations associated with aging at much earlier ages.
GlaxoSmithKline, Xenoport report positive midstage study results from potential pain drugSeptember 17th, 2009 Glaxo, Xenoport report positive pain drug studyNEW YORK — GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study.
Exercise beats shockwaves for chronic shoulder painSeptember 16th, 2009 LONDON - Supervised exercise helps ease chronic shoulder pain better than sound shockwave treatment, a new study suggests. In the study, published in the online British Medical Journal, team of researchers based in Oslo, Norway compared the effectiveness of radial extracorporeal shockwave treatment (low to medium energy impulses delivered into the tissue) with supervised exercises in patients with shoulder pain.
Controlling pain can hasten recovery for kids with cancerSeptember 13th, 2009 WASHINGTON - Controlling pain and discomfort arising from cancer treatment can speed up recovery for children battling the disease, say researchers. Experts at St.
Electrical nerve stimulation may relieve neuropathic pain after spinal cord injurySeptember 12th, 2009 WASHINGTON - A new study has revealed that electrical nerve stimulation can effectively reduce neuropathic pain following a spinal cord injury. Neuropathic pain is often difficult to relieve and usually managed with drugs such as antidepressants or anticonvulsants.
New biomarker can bring rapid relief from major depressionSeptember 11th, 2009 WASHINGTON - Scientists from University of California have identified a biomarker that can help accurately predict whether a particular drug will be effective in treating major depression. During the study, the researchers measured changes in brain-wave patterns using quantitative electroencephalography (QEEG), a non-invasive, computerized measurement that recognizes specific alterations in brain-wave activity.
Iodine must for developing kids' intellectSeptember 10th, 2009 SYDNEY - Intake of iodine is a must for developing the full intellectual potential of children, a new study has revealed. Otago University (O-U) researchers have shown that iodine supplementation to correct the mild deficiency common in children improves their performance in cognitive tests.
New Cytotron treatment effective in treating cancer patients in BangaloreAugust 28th, 2009 BANGALORE - The new Cytotron treatment that includes use of radio frequency, high power non-ionizing, non-thermal electromagnetic waves instead of high frequency radiation has emerged as a popular therapy for cancer patients in Bangalore. Developed by Rajah Vijay Kumar of India in 1987, the Cytotron device helps in tissue regeneration, degeneration and repair for the purposes of treating several chronic or degenerative diseases such as cancer and arthritis.
Soluble fibre 'effective in treating irritable bowel syndrome'August 28th, 2009 LONDON - A new study by researchers from Utrecht University in the Netherlands has suggested that a soluble fibre supplement called psyllium should be the first line of attack in treating irritable bowel syndrome (IBS). In the study, researchers compared adding bran, psyllium and a dummy supplement to sufferers' diets.
